FUJIFILM Diosynth Biotechnologies, a contract development and manufacturing organisation (CDMO), and US-based biotechnology company Regeneron Pharmaceuticals have formalised a decade-long manufacturing partnership valued at over $3bn.
This agreement focuses on the production of biologic medicines within the US, directly impacting millions of patients globally.
The collaboration commits FUJIFILM Diosynth Biotechnologies to providing manufacturing services from its newly planned biopharmaceutical facility in Holly Springs, North Carolina.
This site is set to commence operations during the course of this year, enhancing the company’s capacity for large-scale production. The agreement involves ongoing and future expansions to meet the needs of Regeneron, which is engaged in developing life-transforming medicines.
Regeneron executive vice president and industrial operations and product supply general manager Daniel Van Plew said: “At Regeneron, we have the privilege of making some of the best and most innovative therapeutics in the industry, and we are acutely aware of Regeneron’s impact on people’s lives as we work to help treat or even cure devastating diseases.
“We take our role seriously, and our decision to work with FUJIFILM Diosynth Biotechnologies reflects our belief that they will meet our high standards and grow with us. We are excited about this unique relationship, and we are already working to bring capacity online at FUJIFILM Diosynth Biotechnologies’ biologics manufacturing facility in Holly Springs, North Carolina.”
FUJIFILM Diosynth Biotechnologies operates under FUJIFILM and is known for its expertise in biopharmaceuticals. With over 30 years in the industry, it employs more than 4,800 staff across facilities in the US, the UK, and Denmark.
Its network provides agile supply chain solutions through modular facilities and standardised processes that facilitate technology transfers and scaling.
FUJIFILM Diosynth Biotechnologies president and CEO Lars Petersen said: “We are delighted to be selected as the manufacturing supply partner for Regeneron, utilising our new state-of-the-art facility in Holly Springs, North Carolina.
The Holly Springs site is part of our kojoX interconnected manufacturing network, which provides a first-of-its-kind modular approach with standardised equipment, processes, and procedures across our sites around the globe to help ensure supply chain security and seamless tech transfers.”
Regeneron focuses on drug development for serious diseases using proprietary technologies such as VelociSuite. This technology aids in producing human antibodies and bispecific antibodies.
The company recently emerged as the successful bidder for assets from 23andMe, including its Personal Genome Service and Biobank, valued at $256m. The acquisition is subject to regulatory approvals and is expected to be completed in late 2025.
